

# Effectiveness of protein supplementation combined with resistance exercise training to counteract disproportional fat-free mass loss following metabolic-bariatric surgery: the ENRICHED study.

Published: 26-11-2024

Last updated: 22-12-2024

To compare the effect of a 6-month of enriched care consisting of additional protein intake and regular resistance exercise on the prevalence of disproportional fat-free mass loss (defined as a FFML/WL >30% as main outcome parameter) in patients...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Pending
<b>Health condition type</b>	Other condition
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON57119

### Source

ToetsingOnline

### Brief title

ENRICHED

### Condition

- Other condition

### Synonym

Disproportional fat free mass loss, muscle loss

### Health condition

Disproportioneel vetvrije massa verlies

## Research involving

Human

## Sponsors and support

**Primary sponsor:** Radboud Universitair Medisch Centrum

**Source(s) of monetary or material Support:** ZonMw

## Intervention

**Keyword:** Disproportional fat-free mass loss, Metabolic bariatric surgery, Protein supplementation, Resistance exercise

## Outcome measures

### Primary outcome

Our primary outcome is the prevalence of disproportional FFM loss, defined as FFML/WL >30%. Changes in body composition, such as FFM loss and weight loss (WL) are determined by bioelectrical impedance analysis (BIA) in the total population; and by Dual Energy X-ray Absorptiometry (DXA) in a subgroup (n=100).

### Secondary outcome

Secondary outcomes are body composition, (cardio)metabolic health, muscle strength, muscle function, cardiorespiratory fitness and health-related quality of life, and healthcare consumption.

## Study description

### Background summary

There is a worldwide increase in both prevalence and severity of obesity with currently over 153,000 individuals with severe obesity (i.e., body mass index >40 kg/m<sup>2</sup>) in the Netherlands. Obesity is a chronic disease and a risk factor for cardiovascular disease, type 2 diabetes mellitus and various cancers and negatively impacts both physical and psychological aspects of quality of life.

For these individuals, metabolic-bariatric surgery (MBS) is the most effective approach to achieve long-term weight loss and substantial reduction in comorbidities. Therefore, the number of patients undergoing MBS has exponentially increased up to 12,000 procedures annually in the Netherlands. Previous studies have repeatedly shown that MBS is a cost-effective procedure in terms of disease prevention and related future health care costs. However, long-term health in these patients clearly leaves room for improvement. Post-MBS weight loss consists of both fat mass (FM) and fat-free mass (FFM). Skeletal muscle tissue is the largest component of FFM and is essential for functional capacity, metabolic health, thermoregulation and bone strength. Excessive FM and insufficient FFM, i.e. sarcopenic obesity, have negative health consequences, therefore optimal weight loss strives for FFM maintenance while maximizing FM loss. Our research group showed that the ratio between FM loss and FFM loss varies largely between patients who underwent MBS, with an average percentage of FFM loss of total weight loss ( $=\text{FFML}/\text{WL}$ ) of 20-25% [range 6-54%] at 12 months post-surgery. Our recent data showed that a  $\text{FFML}/\text{WL} \geq 25\%$  was associated with a 1.56 times higher risk for major adverse cardiovascular events and all-cause mortality in middle-aged and older patients. This study highlights that a disproportional composition of weight loss with a relatively high FFM loss could be detrimental for future health. Furthermore, 28-34% of the patients showed a  $\text{FFML}/\text{WL} \geq 25\%$ , underscoring that disproportional  $\text{FFML}/\text{WL}$  is highly prevalent among individuals who underwent MBS. Therefore, MBS care should strive for a more balanced weight loss and strategies that counteract FFM loss during MBS-induced weight loss are required, thereby also improving metabolic health. Interventions with additional protein and resistance exercise are successful in increasing or maintaining muscle mass in other clinical populations. However, studies that examined the impact of additional protein and exercise on FFM in patients who underwent MBS remain inconclusive, presumably due to feasibility issues. Feasibility issues may arise from impaired protein intake, digestion and absorption following the alterations to the gastro-intestinal tract, and/or population-specific barriers towards exercise and diet. These population-specific limitations should be incorporated into new, feasible intervention protocols.

## **Study objective**

To compare the effect of a 6-month of enriched care consisting of additional protein intake and regular resistance exercise on the prevalence of disproportional fat-free mass loss (defined as a  $\text{FFML}/\text{WL} > 30\%$  as main outcome parameter) in patients who underwent MBS compared to standard care.

## **Study design**

This is a multicenter randomized controlled trial that includes four clinical centers of the NOK. Each center will be allocated to either control (standard care) or intervention location (providing enriched care). Participants and

researchers could not be blinded due to practical considerations. Patients will be informed and recruited during the preoperative care program. An initial screening is performed by the standard care team to determine eligibility based on in- and exclusion criteria. Informed consent will be collected prior to any measurements.

## **Intervention**

During the 6-month intervention period, the control group follows standard care protocols, while standard care is complemented by additional protein intake, resistance training and counseling sessions with dietitians and physiotherapists for the enriched care group. Patients in the enriched care group will be provided with powdered whey protein supplements for the first twelve postoperative weeks. To enhance tolerability and, consequently, compliance, patients are instructed to follow a gradually increasing protein supplementation protocol. This protocol includes 15-20 grams of whey supplementation daily for 4 weeks, followed by 15-20 grams twice daily for the next 4 weeks, and finally 15-20 grams thrice daily for an additional 4 weeks. After twelve weeks, patients are enrolled in counseling sessions with NOK dietitians, which focuses on the transition from protein supplements to protein-rich food products, and implementing these products into the daily intake pattern. Furthermore, these patients will be invited to join supervised group sessions of resistance exercise at their NOK center once a week. Next to these sessions, patients are instructed to perform resistance exercises in their home environment on a daily base. They will be guided through this process with the help of additional counseling sessions with a physiotherapist. Given the gastrointestinal and physical post-operative limitations, the protein and resistance training interventions will commence 2 and 6 weeks after the surgical procedure, respectively. During the 6-month follow-up, all patients are assigned to standard care. Measurements are performed before MBS, at 3, 6, and 12 months follow-up post-baseline.

## **Study burden and risks**

Participating in this study brings negligible risks. The products will be produced according to the HACCP/ISO22000 regulations in certified facilities and using approved and commercially available ingredients. Resistance training is performed with regular supervision of trained physiotherapists and adjusted to the participant's needs and ability. Subject with an elevated risk related to this study will be excluded of participation. Measures related to this study are blood samples, body composition analysis, muscle strength/function tests, submaximal exercise tests, physical activity and dietary intake assessments and questionnaires/diaries. These measures are minimally invasive and can be graded as \*negligible risk\*.\*

## Contacts

### Public

Radboud Universitair Medisch Centrum

Geert Grooteplein Zuid 10  
Nijmegen 6525 GA  
NL

### Scientific

Radboud Universitair Medisch Centrum

Geert Grooteplein Zuid 10  
Nijmegen 6525 GA  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

### Inclusion criteria

- A scheduled bariatric surgery procedure (i.e., a RYGB or sleeve gastrectomy)
- Participation in the NOK care program
- Able to understand and perform the study procedures

### Exclusion criteria

- Allergic or sensitive for milk proteins, or lactose intolerant
- Diagnosed renal insufficiency
- Diagnosed intestinal diseases influencing the uptake of protein (i.e., active inflammatory bowel disease, Crohn's disease)
- Inability to perform any resistance training exercises (e.g., severe physical limitations)

- Inability to comprehend scheduled procedures (e.g., language barriers)

## Study design

### Design

Study type:	Interventional
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)

**Primary purpose:** Prevention

### Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-01-2025
Enrollment:	400
Type:	Anticipated

## Ethics review

Approved WMO	
Date:	26-11-2024
Application type:	First submission
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

**Other (possibly less up-to-date) registrations in this register**

No registrations found.

**In other registers**

Register	ID
CCMO	NL87367.091.24